ASCO 2024 | Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer
Erika Hamilton, MD, from the Sarah Cannon Research Institute in Nashville, TN, presents updated findings from the Phase III DESTINY-Breast03 trial (NCT03529110) comparing the efficacy and safety of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer who had received at least one prior anti-HER2 regimen. The updated results, with a median follow-up of 43.0 months for T-DXd and 35.4 months for T-DM1, show a clinically meaningful improvement in overall survival (OS), progression-free survival (PFS), and PFS on next line of therapy (PFS2) with T-DXd. Notably, the safety profile of T-DXd remains manageable, with no cumulative toxicities observed over longer follow-up. These findings reinforce the superiority of T-DXd over T-DM1 as a treatment option for HER2-positive metastatic breast cancer. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Accutar Biotechnology; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Entos; Fosun Pharma; Genentech/Roche; Gilead Sciences; Jazz Pharmaceuticals; Jefferies; Lilly; Medical Pharma Services; Mersana; Novartis; Olema Pharmaceuticals; Pfizer; Stemline Therapeutics; Tempus; Theratechnologies; Tubulis GmbH; Verascity Science; Zentalis
Research Funding – Abbvie; Accutar Biotech; Acerta Pharma; ADC Therapeutics; Akeso Biopharma; Amgen; Aravive; ArQule; Artios; Arvinas; AstraZeneca; AtlasMedx; BeiGene; Black Diamond Therapeutics; Bliss Biopharmaceutical; Boehringer Ingelheim; Bristol-Myers Squib; Cascadian Therapeutics; Clovis Oncology; Compugen; Context Therapeutics; Cullinan Oncology; Curis; CytomX Therapeutics; Daiichi Sankyo; Dana Farber Cancer Hospital; Dantari; Deciphera; Duality Biologics; eFFECTOR Therapeutics; Eisai; Ellipses Pharma; Elucida Oncology; EMD Serono; Fochon Pharmaceuticals; Fujifilm; G1 Therapeutics; Genentech/Roche; Gilead Sciences; H3 Biomedicine; Harpoon; Hutchison MediPharma; Immunogen; Immunomedics; Incyte; Infinity Pharmaceuticals; Inspirna; InventisBio; Jacobio; K-Group Beta; Karyopharm Therapeutics; Kind Pharmaceuticals; Leap Therapeutics; Lilly; Loxo; Lycera; MabSpace Biosciences; Macrogenics; MedImmune; Mersana; Merus; Millennium; Molecular Templates; Myriad Genetics; Novartis; Nucana; Olema Pharmaceuticals; OncoMed; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals; Orinove; Orum Therapeutics; Pfizer; PharmaMar; Pieris Pharmaceuticals; Pionyr; Plexxikon; Prelude Therapeutics; ProfoundBio; Radius Health; Regeneron; Relay Therapeutics; Repertoire Immune Medicines; Rgenix; Seagen; Sermonix Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Stem CentRx; Stemline Therapeutics; Sutro Biopharma; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; TapImmune Inc.; Tesaro; Tolmar; Torque; Treadwell Therapeutics; Verastem; Zenith Epigenetics; Zymeworks
